News Sentiment

LXRX sentiment intelligence

Lexicon Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.22 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-4.3% over one week, +15.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend active 15.6% over four weeks
Fair value 56.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
Stock Titan 10
Simply Wall Street 3
www.marketscreener.com 3
TradingView 3
TradingKey 3
GlobeNewswire 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 23
Balance sheet 2
Regulatory and legal 2
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Simply Wall Street Direct company coverage

What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders

Lexicon Pharmaceuticals (LXRX) was recently included in several Russell indexes, including the Russell 2000 and 3000, which could boost its trading liquidity and attract new investors. However, this inclusion doesn't change the company's fundamental investment narrative, which st

Tone
Positive 62/100
Event
Balance sheet
Published
10 Jul 2026 08:40
Source
Simply Wall Street
MarketBeat Direct company coverage

Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Jul 2026 $LXRX

Lexicon Pharmaceuticals (LXRX) experienced a 21.08% increase in short interest as of June 30, 2026, reaching 30.78 million shares, representing 8.06% of the public float. The short interest ratio or "days to cover" stands at 4.4 days, indicating the time it would take to cover al

Tone
Negative 35/100
Event
Market update
Published
10 Jul 2026 07:11
Source
MarketBeat
AD HOC NEWS Direct company coverage

Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin

Lexicon Pharmaceuticals (LXRX) is maintaining its focus on diabetes and metabolic disease therapies, emphasizing its pipeline strategy within the competitive US biopharma market. The company develops targeted therapies for defined patient populations, concentrating on cardiometab

Tone
Positive 67/100
Event
Regulatory and legal
Published
07 Jul 2026 21:51
Source
AD HOC NEWS
Stock Titan Direct company coverage

If You Invested $1,000 in Lexicon Pharmaceuticals Inc (LXRX)

This article examines the historical performance of investing $1,000 in Lexicon Pharmaceuticals Inc (LXRX) over one, five, and ten years, comparing its returns to the S&P 500. It also provides an in-depth profile of Lexicon Pharmaceuticals, detailing its biopharmaceutical product

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 04:09
Source
Stock Titan
Insider Monkey Direct company coverage

Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion

Lexicon Pharmaceuticals (LXRX) has seen more than a 15% gain over the past month, largely due to its inclusion in the Russell 3000 index and strong Q1 2026 earnings, which surpassed expectations significantly. The company reported $21.1 million in revenue, a 1,523% year-over-year

Tone
Positive 74/100
Event
Earnings
Published
03 Jul 2026 13:39
Source
Insider Monkey
Simply Wall Street Direct company coverage

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)

Lexicon Pharmaceuticals, Inc. was added to various Russell indexes on June 27, 2026, increasing its visibility to institutional investors. While this expanded index inclusion is significant for potential trading volume and ownership, the company's core investment narrative still

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 04:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Lexicon Pharmaceuticals (LXRX) Joins Russell Indexes, Is The Stock Still A Bargain?

Lexicon Pharmaceuticals (LXRX) has been added to multiple Russell indexes, which is expected to increase its visibility among investors after a period of strong share price growth. Despite a "most popular narrative" suggesting the stock is 30% undervalued at $3.77 due to its prom

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 05:10
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark

Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2500 Growth Benchmark. The biopharmaceutical company is actively involved in the research and development of drug candidates and the commercialization of INPEFA (sotagliflozin) for heart failure and type

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 16:26
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark

Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2000 Growth Benchmark. The biopharmaceutical company focuses on researching and developing drug candidates and commercializing INPEFA (sotagliflozin), which reduces cardiovascular risks. Lexicon is also d

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 15:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark

Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 3000E Growth Benchmark. The biopharmaceutical company focuses on researching, developing, and commercializing drug candidates, including INPEFA (sotagliflozin) for cardiovascular and kidney conditions, pi

Tone
Positive 68/100
Event
Market update
Published
29 Jun 2026 03:44
Source
www.marketscreener.com
StocksToTrade Direct company coverage

LXRX Surges As Traders Pounce On Strong Breakout

Lexicon Pharmaceuticals Inc. (LXRX) stock has surged by 11.76% due to bullish sentiment driven by promising drug development progress. The stock has broken out from low $2s to above $2.55, indicating strong buying pressure despite the company's significant operating losses. Analy

Tone
Positive 75/100
Event
Market update
Published
28 Jun 2026 15:37
Source
StocksToTrade
StocksToTrade Direct company coverage

LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders

Lexicon Pharmaceuticals Inc. (LXRX) stock has climbed by 11.76% due to positive drug development news and bullish investor sentiment. Despite rapid revenue growth, the company faces deep losses, but strong liquidity provides a runway for operations. Technical analysis indicates a

Tone
Positive 82/100
Event
Earnings
Published
27 Jun 2026 15:10
Source
StocksToTrade
Timothy Sykes Direct company coverage

LXRX Climbs As Bulls Press Multi-Day Breakout

Lexicon Pharmaceuticals Inc. (LXRX) is experiencing a multi-day breakout driven by positive drug development news, with its stock climbing significantly. Despite strong revenue growth, the company faces deep losses, but its strong balance sheet and high liquidity provide a runway

Tone
Positive 66/100
Event
Earnings
Published
27 Jun 2026 14:10
Source
Timothy Sykes
Investing.com Nigeria Direct company coverage

Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com

Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing significant momentum with increases of approximately 14% over the past week, 86% over six months, and 99% year-to-date, reflecting a 206.37% increase over the last year. Despite this surge and a strong

Tone
Positive 72/100
Event
Market update
Published
27 Jun 2026 14:10
Source
Investing.com Nigeria
Investing.com Direct company coverage

Lexicon Pharmaceuticals stock hits 52-week high at $2.53

Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing strong momentum with significant gains over the past week, six months, and year-to-date. This performance, coupled with revenues surging to $21.1 million in Q1 2026, reflects investor confidence, though

Tone
Positive 85/100
Event
Market update
Published
27 Jun 2026 13:39
Source
Investing.com
TradingView Direct company coverage

Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX)

This article provides an overview of Lexicon Pharmaceuticals, Inc. (LXRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financials, such as recent revenue and net income, market capitalization, and upcoming earnin

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 00:38
Source
TradingView
TradingView Direct company coverage

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon Pharmaceuticals (LXRX) is highlighted as an investment opportunity due to its advancing cardiometabolic franchise, primarily driven by its drug sotagliflozin (Inpefa). The company is pursuing label expansion for sotagliflozin into hypertrophic cardiomyopathy and type 1 di

Tone
Positive 85/100
Event
Market update
Published
22 Jun 2026 14:40
Source
TradingView
AD HOC NEWS Direct company coverage

Lexicon Pharmaceuticals Stock - Sunday background on strategy and trials

This article provides background on Lexicon Pharmaceuticals (LXRX), a biotech company focusing on cardiovascular and metabolic diseases. It highlights the company's approved heart failure drug Inpefa, its clinical development strategy, and financial considerations. While there wa

Tone
Positive 63/100
Event
Market update
Published
21 Jun 2026 18:10
Source
AD HOC NEWS
TradingKey Direct company coverage

Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lexicon Pharmaceuticals Inc (LXRX) has an earnings forecast score of 7.60, ranking 281st in the Biotechnology & Medical Research industry. Analysts project an average price target of $1.90 with a "Buy" rating based on 5 analysts. The company's recent EPS was -$0.04, with the next

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 06:41
Source
TradingKey
TradingKey Direct company coverage

Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis

Lexicon Pharmaceuticals Inc (LXRX) currently holds a financial score of 8.90, ranking 23rd in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 157

Tone
Positive 77/100
Event
Earnings
Published
18 Jun 2026 05:41
Source
TradingKey
TradingKey Direct company coverage

Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence

Lexicon Pharmaceuticals Inc (LXRX) has an institutional shareholding score of 5.00, placing it 133rd out of 388 in its industry. The institutional shareholding proportion is 67.79%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder

Tone
Positive 64/100
Event
Earnings
Published
18 Jun 2026 02:41
Source
TradingKey
Barchart.com Direct company coverage

Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 – DelveInsight | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith

The Peripheral Neuropathic Pain market is projected for significant growth by 2034, driven by increasing disease prevalence, awareness, and the launch of multiple pipeline products. In 2023, the global market was valued at approximately USD 12,000 million, with the US showing the

Tone
Positive 66/100
Event
Market update
Published
16 Jun 2026 22:09
Source
Barchart.com
IndexBox Direct company coverage

Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global Drugmaker - News and Statistics

This article compares Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE), highlighting the contrast between a small, growing biotech firm and a large, established pharmaceutical giant. It delves into their recent financial performances, noting Lexicon's significant revenue growth bu

Tone
Neutral 50/100
Event
Earnings
Published
11 Jun 2026 15:10
Source
IndexBox
Stock Titan Direct company coverage

Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares

Lexicon Pharmaceuticals director Ivan Cheung converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, at a price of $0.00 per share. Following this non-cash equity award event, Cheung directly holds 89,312 common shares, with no remaining restricted stoc

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 17:39
Source
Stock Titan
Stock Titan Direct company coverage

Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake

Lexicon Pharmaceuticals director Sam L. Barker converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, receiving 89,312 shares at $0.00 per share. This transaction was an equity compensation event, not an open-market trade. Following the conversion, Bar

Tone
Neutral 50/100
Event
Deals and strategy
Published
05 Jun 2026 04:08
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity

LEXICON PHARMACEUTICALS, INC. director Christopher J. Sobecki exercised 89,312 restricted stock units, converting them into an equivalent number of common shares. Following this transaction, his direct holdings in the company amount to 293,177 shares of common stock. The transact

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 20:39
Source
Stock Titan